Trials / Terminated
TerminatedNCT00593554
Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies
A Phase II Trial of Haplotype Mismatched Hematopoietic Stem Cell Transplantation Using Highly Purified CD34 Cells in Patients With Hematological Malignancies
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Sherif S. Farag · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if haplotype-mismatched HSCT is associated with an improvement in treatment-related mortality (TRM) rate at 6 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Total Body Irradiation | 8 Gy on Day -9 |
| DRUG | Thiotepa | 5 mg/kg/d on Day -8 to -7 |
| DRUG | Fludarabine | 40 mg/m2/d on Day -6 to -3 |
| BIOLOGICAL | Rabbit ATG | 2.5 mg/kg/d on Day -5 to -2 |
| DRUG | Palifermin | 60 ug/kg (actual body weight) on Day -9 to -7 and Day 0 to +2 |
Timeline
- Start date
- 2007-08-07
- Primary completion
- 2016-08-27
- Completion
- 2017-07-28
- First posted
- 2008-01-15
- Last updated
- 2018-04-10
- Results posted
- 2018-04-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00593554. Inclusion in this directory is not an endorsement.